ABBOTT LABORATORIES Research and Development Asset Acquired Other than Through Business Combination, Written-off
ABBOTT LABORATORIES (ABT) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $288.00 million for the 12-month period ending 2012-12-31, per its 10-K filed 2013-02-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2013-02-15
- ABBOTT LABORATORIES research and development asset acquired other than through business combination, written-off for the quarter ending 2012-12-31 was $28.00M, a 93.00% decline year-over-year.
- ABBOTT LABORATORIES research and development asset acquired other than through business combination, written-off for the quarter ending 2012-09-30 was $0.00.
- ABBOTT LABORATORIES research and development asset acquired other than through business combination, written-off for the quarter ending 2012-06-30 was $110.00M, a 36.23% decline year-over-year.
- ABBOTT LABORATORIES research and development asset acquired other than through business combination, written-off for the quarter ending 2012-03-31 was $150.00M, a 50.00% increase year-over-year.
- ABBOTT LABORATORIES research and development asset acquired other than through business combination, written-off for fiscal 2012 was $288.00M, a 57.17% decline from fiscal 2011.
- ABBOTT LABORATORIES research and development asset acquired other than through business combination, written-off for fiscal 2011 was $672.50M, a 114.72% increase from fiscal 2010.
- ABBOTT LABORATORIES research and development asset acquired other than through business combination, written-off for fiscal 2010 was $313.20M, a 84.24% increase from fiscal 2009.
- ABBOTT LABORATORIES research and development asset acquired other than through business combination, written-off for fiscal 2009 was $170.00M.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|---|---|---|
| 2012-12-31 | $28.00M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | $28.00M derived: sum of 2 quarters · filed 2013-02-15 | $138.00M derived: sum of 3 quarters · filed 2013-02-15 | $288.00M 10-K · filed 2013-02-15 |
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $110.00M derived: sum of 2 quarters · filed 2012-11-07 | $260.00M 10-Q · filed 2012-11-07 | $660.00M derived: sum of 4 quarters · filed 2013-02-15 |
| 2012-06-30 | $110.00M 10-Q · filed 2012-11-07 | $260.00M 10-Q · filed 2012-08-07 | $660.00M derived: sum of 3 quarters · filed 2013-02-15 | $660.00M derived: sum of 4 quarters · filed 2013-02-15 |
| 2012-03-31 | $150.00M 10-Q · filed 2012-11-07 | $550.00M derived: sum of 2 quarters · filed 2013-02-15 | $550.00M derived: sum of 3 quarters · filed 2013-02-15 | $722.50M derived: sum of 4 quarters · filed 2013-02-15 |
| 2011-12-31 | $400.00M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | $400.00M derived: sum of 2 quarters · filed 2013-02-15 | $572.50M derived: sum of 3 quarters · filed 2013-02-15 | $672.50M 10-K · filed 2013-02-15 |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $172.50M derived: sum of 2 quarters · filed 2012-11-07 | $272.50M 10-Q · filed 2012-11-07 | $510.70M derived: sum of 4 quarters · filed 2013-02-15 |
| 2011-06-30 | $172.50M 10-Q · filed 2012-08-07 | $272.50M 10-Q · filed 2012-08-07 | $510.70M derived: sum of 3 quarters · filed 2013-02-15 | $510.70M derived: sum of 4 quarters · filed 2013-02-15 |
| 2011-03-31 | $100.00M 10-Q · filed 2012-05-08 | $338.20M derived: sum of 2 quarters · filed 2013-02-15 | $338.20M derived: sum of 3 quarters · filed 2013-02-15 | $413.20M derived: sum of 4 quarters · filed 2013-02-15 |
| 2010-12-31 | $238.20M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | $238.20M derived: sum of 2 quarters · filed 2013-02-15 | $313.20M derived: sum of 3 quarters · filed 2013-02-15 | $313.20M 10-K · filed 2013-02-15 |
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $75.00M derived: sum of 2 quarters · filed 2011-11-04 | $75.00M 10-Q · filed 2011-11-04 | |
| 2010-06-30 | $75.00M 10-Q · filed 2011-08-04 | $75.00M 10-Q · filed 2011-08-04 | ||
| 2009-12-31 | $170.00M 10-K · filed 2012-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |